Our new Global Public Health Strategy and opening of new operations in Cape Town.

Cape Town, South Africa, (6 April, 2016) – Janssen’s parent company, Johnson & Johnson, today announced the official launch of its global public health strategy at the opening of its companies’ on-the-ground global public health operations in Cape Town, South Africa.

The initial implementation of the strategy starts with this new site in Africa, and will focus on three core areas: HIV, Tuberculosis (TB), and Maternal, Newborn and Child Health. The company plans to expand its focus areas to address other unmet global health needs and its geographic reach.

Global Public Health Strategy

“This is a model based on innovation, collaboration, and local empowerment that aims to address life threatening issues and deliver measurable results to improve outcomes for patients, families and communities, first across Africa, and more globally in the longer term,” said Paul Stoffels, M.D., Chief Scientific Officer and Worldwide Chairman, Pharmaceuticals, Johnson & Johnson. “By directly engaging with and empowering researchers and the health care community across South Africa, we will be better able to direct our resources and advance innovations that can lead to greater impact. We think this can work anywhere in the world, but our urgency right now has to be in Africa because of the patients’ needs.”

On-the-ground operations

The opening of the Cape Town operations expand upon the company’s legacy and presence in Africa, which began in 1936, and brings additional investments to the more than 1,500 employees and three manufacturing sites within the Johnson & Johnson Family of Companies, including Janssen, which are already present on the continent. Global public health satellite offices in Kenya and Ghana are planned to follow later this year.

Learn more about Janssen’s participation in this Global Public Health Strategy here.